About the Speaker:-Dr. Praveen Kumar Vemula is Professor and Dean of Research at the Institute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore. He obtained PhD from IISc. Subsequently he did postdoctoral research at City College of New York. Subsequently, he has worked as Ewing Marion Kauffman Foundation Entrepreneurial Postdoc Fellow at Harvard Medical School. His expertise is developing chemical technologies for medical applications. His work spans the fields of biomaterials, drug discovery, drug delivery, medical devices, and chemical biology.

Vemula has published >95 peer-reviewed papers, has given >300 national and international invited lectures including 3 TEDx talks, and has >30 issued or pending national/international patents, which have been licensed to multiple biotech companies. Several technologies developed in his lab have formed the foundation for multiple products on the market, and currently under development.

Based on his technologies he has formed 8 startup companies. Thus far, >25 products that are developed based on his technologies are in the market worldwide.

His work has been recognized by:
Institute of Chemical Technology-Royal Society of Chemistry (ICT-RSC) Innovation Award 2024
National Biotechnology Innovation Award-2023
DBT-Product, Process, Technology Development and Commercialization Award 2020
GYTI-SRISTI-BIRAC Award-2019

Abstract:- Our lab is focusing on clinical translational research through biomaterials and chemical biology programs. By using chemical design tools, we have been developing therapeutic and prophylactic technologies for medical applications. For example, in this talk a few examples will be discussed in detail. We will discuss about developing prophylactic technologies to prevent pesticide-induced toxicity and lethality that is prevalent in farmers in India and developing countries. Furthermore, we will discuss how our efforts in drug discovery and drug delivery areas to develop innovative technologies that will have enormous clinical implication. Overall, we will see a snapshot of various technologies that could be developed in the lab, and translated into the clinic/market.